COMPANY PROFILE

Surge

Explore full profile

Innovative fingerprinting of the immune system with AI to holistically improve the perioperative standard-of-care

Paris, FranceFounded 2021Biotech & Life Sciences

Valuation $10–25M Last recorded · 2024

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Surge

Surge.care is a health-tech startup based in Silicon Valley, led by a team of six individuals from prestigious institutions such as Stanford, Harvard, Sorbonne, and Ecole Polytechnique. The company operates in the healthcare sector, specifically focusing on the development of products and services that enhance the capabilities of healthcare teams.

Read full description

The company's flagship technology, PreCyte, is the result of a decade-long research. PreCyte is an innovative immunological fingerprinting technology that combines high-resolution exploration of the human immune system with the identification of actionable predictive information. This technology is designed to optimize preventive strategies and aid in the development of new treatments or medical devices.

Surge.care's business model revolves around leveraging their proprietary AI-powered platform to identify reliable immune signatures of specific clinical outcomes. This information is biologically interpretable and clinically actionable, allowing researchers and clinicians to focus on the most impactful interventions.

The company's services are particularly beneficial for surgical units, where postoperative infections are a common and costly complication. With an average cost of $72,000 per postoperative infection, Surge.care's technology can potentially save a surgical unit up to $26 million per year.

In summary, Surge.care is a health-tech company that uses AI and immunological fingerprinting technology to enhance healthcare outcomes, particularly in the area of postoperative care.

Source: Dealroom company data